All News

RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

Read Article
RheumNow Podcast square

RheumNow Podcast - RWCS 2022 Roundup (2.19.2022)

Jack Cush, MD

Drs. Jack Cush and Artie Kavanaugh review the highlights of the RWCS (Rheumatology Winter Clinical Symposium) from Maui.


Read Article
2021,year

2021 Rheumatology Year in Review

Jack Cush, MD

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
PSS.scleroderma.arthritis.contractures

Autoantibody Associations in Systemic Sclerosis

Jack Cush, MD

Analysis of two large cohorts of systemic sclerosis (SSc) patients shows a signfiicant minority of patients to have autoantibodies typical of rheumatoid erosive arthrits, but their presence in SSc patients was associated with unique manifestations of SSc. 

Read Article
Lungs ILD

Best of 2021: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Jack Cush, MD

Genentech announced March 4th that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults S

Read Article
RheumNow Podcast square

Indications Awaiting (12.17.21)

Jack Cush, MD

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory approvals, plus 3 new cases from rheumatologists.

Read Article
ICYMI: Good review of Diagnosis and Treatment of Pulmonary Sarcoidosis in JAMA. - Lung progression (in only 10%) assoc w/ 12-18% 5yr mortality - Sx Sarcoid w/ Lung: start Pred 20 to 40 mg/d for 2 -6 wks - Steroid sparing w/ MTX, AZA or TNFi https://t.co/Ue4V1uAhRF https://t.co/5ap3bPzoNk

Links:

Dr. John Cush RheumNow ( View Tweet)
Late Onset Scleroderma Renal Crisis: A Case Control Analysis - Dr. Yoon Qiu at RWCS 2022 https://t.co/G1M7Lzhk7P https://t.co/hPRL8WFdUf

Links:

Dr. John Cush RheumNow ( View Tweet)
Using whole gut scintigraphy & gastric emptying studies on 97 systemic sclerosis pts, researchers found 35% had gastroparesis, and these pts also had abnormal transit thru out the GI tract. High anti-CENP-B titers assoc w/ slower gastric emptying https://t.co/lQgQe5Uo9H

Links:

Dr. John Cush RheumNow ( View Tweet)

Nailfold Capillaroscopy doesnt have to be expensive: use handheld Carson Microbrite (~$10) 10x or 20 x handheld microscope (w/ KY gel) to evaluate #Raynauds #scleroderma https://t.co/8AMsEnaiir https://t.co/JZO0s8xbXA https://t.co/scJTBOD7OS #RWCS2022

Links:

Dr. John Cush RheumNow ( View Tweet)

Future considerations and treatment directions in systemic sclerosis per Dr Steen. #RWCS2022 @RWCSmtg https://t.co/FaJaJ9G5lU
Dr. John Cush RheumNow ( View Tweet)
Subsets of scleroderma defined by autoantibodies. #RWCS2022 @RWCSmtg https://t.co/ywe0yrHmWd
Dr. John Cush RheumNow ( View Tweet)
Many failed clinical trials in Scleroderma in the past. #RWCS2022 @RWCSmtg https://t.co/2PBfHAnqWu
Dr. John Cush RheumNow ( View Tweet)
Scleroderma ANA associations thru the ages. Dr. Virginia Steen @RWCSmtg #RWCS2022 https://t.co/U64gpnCgS8
Dr. John Cush RheumNow ( View Tweet)
Dr Virginia Steen at #RWCS2022. On scleroderma lung Dz that worsens outcomes https://t.co/n7IV8UVI2N https://t.co/kLmiKiseur
Dr. John Cush RheumNow ( View Tweet)
👌Superb review of #SSc ILD by @sclerodermaUM #ACR21 👉EARLY/SUBCLINICAL is NOT Mild ILD 👉MMF 1st 👉TCZ in combination for progressive phenotype/progression 👉Nintedanib:start slow, uptitrate for GI tolerability 👉Early HSCT referral (early dcSSc, FVC&DLCO 45-80%, Normal🫀) https://t.co/MUOhc3PakH
Ashima Makol MD AshimaMakol ( View Tweet)
Prof. Ami Shah: Patients with #scleroderma have an ⬆ risk of #cancer vs. general population 📌Data from 3 recent meta-analysis: Scleroderma pts have 1.4 to 1.8 fold increased risk of cancer @RheumNow #ACR21 https://t.co/4uQN6y3tIn
sheila RHEUMarampa ( View Tweet)
Dr. Ami Shah shares her approach to cancer screening in patients with #scleroderma👇 @RheumNow #ACR21 https://t.co/chmlGe4iyl
sheila RHEUMarampa ( View Tweet)
Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch
Janet Pope Janetbirdope ( View Tweet)
Dr Ami Shah - Scleroderma & Cancer: 🛑 ⬆️ risk of ca around the time of dx in SSc patients with RNA-pol-III (especially first 5 years after dx), anti-Th/To protective? 🛑Her approach for ca screening in newly diagnosed with SSc pts and red flags as below #ACR21 #ACRambassador https://t.co/2VcWn2UInm
Didem Saygin, MD didemsayginmd ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×